H.R. 5160In markupHealth care
Federal stem cell and cord blood match programs extended to 2031
Data as of July 11, 2026
HR 5160 renews two federal transplant-match programs through 2031 and raises yearly funding to roughly $33M starting in 2027.50-second read · 5 questions answered below
Decoded
What does this do?
HR 5160 renews the C.W. Bill Young Cell Transplantation Program and the federal cord blood inventory program through 2031. Both programs have been in place since 2005 and are unchanged in structure. The bill does not create any new programs.
Who does it affect?
Patients with blood diseases such as leukemia or sickle cell disease who need stem cell or bone marrow transplants and lack a family donor are the primary population served. Hospitals, transplant centers, and cord blood banks that rely on these national registries are also affected.
Why does it matter?
Without continued federal authorization, the national registries and cord blood banks that support donor matching would lose their funding base. Patients who depend on those registries to find unrelated donors would face gaps in the availability of matching and stored cord blood supplies.
What does it cost, and who pays?
- ~$31M per year current funding
- Rises to ~$33M starting 2027
- Covers matching, collection, storage
Where does it stand?
- Introduced
- House committee — You are here
- House vote
- Senate
- President's desk
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
AI-drafted summary. Verify it against the official text before you act on it.
Three steps: where you stand, your script, the call.
Make the callSee how a call works
Official title
Stem Cell Therapeutic and Research Reauthorization Act of 2025
- Introduced:
- September 4, 2025
- Latest action:
- May 21, 2026
Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
Read the official bill on Congress.govMake the call
Three steps: where you stand, your script, the call.